this post was submitted on 27 May 2024
24 points (100.0% liked)

TechTakes

1427 readers
141 users here now

Big brain tech dude got yet another clueless take over at HackerNews etc? Here's the place to vent. Orange site, VC foolishness, all welcome.

This is not debate club. Unless it’s amusing debate.

For actually-good tech, you want our NotAwfulTech community

founded 1 year ago
MODERATORS
 

Have a sneer percolating in your system but not enough time/energy to make a whole post about it? Go forth and be mid!

Any awful.systems sub may be subsneered in this subthread, techtakes or no.

If your sneer seems higher quality than you thought, feel free to cut’n’paste it into its own post, there’s no quota for posting and the bar really isn’t that high

The post Xitter web has spawned soo many “esoteric” right wing freaks, but there’s no appropriate sneer-space for them. I’m talking redscare-ish, reality challenged “culture critics” who write about everything but understand nothing. I’m talking about reply-guys who make the same 6 tweets about the same 3 subjects. They’re inescapable at this point, yet I don’t see them mocked (as much as they should be)
Like, there was one dude a while back who insisted that women couldn’t be surgeons because they didn’t believe in the moon or in stars? I think each and every one of these guys is uniquely fucked up and if I can’t escape them, I would love to sneer at them.

you are viewing a single comment's thread
view the rest of the comments
[–] skillissuer@discuss.tchncs.de 20 points 5 months ago

a take from Derek Lowe on AI drugs: https://www.science.org/content/blog-post/ai-drugs-so-far

They began with a list of AI-focused companies (114!), then matched that up with the clinical projects that are reported for them (39 of them).

If you look at the 2023 figures, the authors have 24 AI-discovered targets, 22 AI-optimized small molecules, 4 antibodies, 6 vaccines, and 10 repurposed compounds. So what do we think about those figures?

shot

What you will see is that in almost every case, these targets were already known to be implicated in the disease under investigation. In some of these examples, in fact there are several drugs already in the clinic targeting the same proteins, or even therapies that are already on the market working through the same mechanisms

chaser

That colors my entire view of this paper - which was written by a prominent consulting firm, why did you ask.